Indian Generics Drug Market to be Privileged from Patent Expiries

According to our new report, “Booming Generics Drug Market in India”, the Indian generic drugs market has posted an impressive growth pattern over the last few years. Currently, the Indian pharmaceutical market is fully dominated by generic drugs and in the near future, this scenario is likely to remain the same. In FY 2010, the share of generic drugs in the overall pharmaceutical market was estimated to be around 79.2% and by FY 2013, the share is likely to escalate to around 80.5%.

 

We have found that generic drugs developed by India are now distributed and sold in several parts of the globe that, in turn, has augmented the demand for Indian generic drugs. With the key drugs going off-patents in the coming future, which also include blockbusters, there is an immense opportunity for Indian generics manufacturers to strengthen their market share in countries, such as the US, Europe, and Japan.

 

The report, “Booming Generics Drug Market in India”, covers almost all the key aspects of the Indian generic drugs market and investigates the current trends that may impact the market performance. It provides an effective insight into the past market statistics, current developments, and future outlook. The report illustrates the key opportunities for Indian generics manufacturers in different parts of the world and presents the content through reliable statistics.

 

The report is an outcome of an extensive research and prudent analysis of the Indian generics market that evaluates all the necessary market drivers and their features. The report also presents a detailed overview of the regulatory system concerned with the Indian pharmaceutical and generics market. While forecasting the key areas in the report, our analysts used reliable methods and techniques that sought to establish a more realistic outlook. Overall, the report is meant to provide clients with an effective source of knowledge and statistics that will help in making investment decisions.